Reproductive health and endocrine disruption in women with breast cancer: a pilot study

The Commission on Cancer’s standard 3.3 represents a paradigm shift in the care of cancer survivors, recommending that survivors receive a treatment summary and survivorship care plan (SCPs). A focus on older breast cancer survivors is needed, as they are the majority of the breast cancer population and their experiences and perspectives of SCPs is limited in the literature. This pilot study utilized a mixed methods approach (focus groups and self-report questionnaire data) to gather information on older (≥65 years) breast cancer survivors’ perspectives of their SCPs, cancer survivorship, and communication with their health-care providers. The questionnaire was completed individually by the participants prior to the focus group and contained items on basic demographics and their health status following cancer treatment. The focus groups indicated that only a minority of women actually developed a SCP. Those who developed a SCP in collaboration with their providers valued the personal care and attention received. However, some participants reported poor communication with their providers and within their health-care team, resulting in frustration and confusion. Participants’ suggestions for ideal SCPs included better education and personalization, particularly in appropriate nutrition and exercise, and managing side effects and comorbidities. Lastly, the women believed that additional long-term care resources, such as health coaches, were important in improving their survivorship. These findings provide insight into enhancing the content, communication, and application of SCPs to improve the survivorship experience of older breast cancer survivors.

Download Full-text

A pilot study on thoracoscopic internal mammary lymphatic chain dissection for breast cancer

The Breast ◽

10.1016/j.breast.2008.08.002 ◽

2008 ◽

Vol 17 (6) ◽

pp. 568-573 ◽

Cited By ~ 14

Author(s):

Qingqing He ◽

Jun Jiang ◽

Xinhua Yang ◽

Linjun Fan ◽

Meiqin Guo ◽

...

Keyword(s):

Breast Cancer ◽

Pilot Study ◽

Internal Mammary

Download Full-text

343 Value of axillary ultrasound as a pre-operative staging procedure in breast cancer – a pilot study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)70369-4 ◽

2010 ◽

Vol 8 (3) ◽

pp. 158

Author(s):

M.J. Stokes ◽

P. Davey ◽

J. McKillen ◽

C.W. Majury ◽

J. Newell ◽

...

Keyword(s):

Breast Cancer ◽

Pilot Study ◽

Axillary Ultrasound ◽

Operative Staging

Download Full-text

Vibration Perception Threshold and Heart Rate Variability as methods to assess chemotherapy-induced neuropathy in women with breast cancer – a pilot study

Cancer Treatment and Research Communications ◽

10.1016/j.ctarc.2021.100426 ◽

2021 ◽

pp. 100426

Author(s):

Simone Diedrichsen Marstrand ◽

Kristian Buch-Larsen ◽

Michael Andersson ◽

Lars Thorbjørn Jensen ◽

Peter Schwarz

Keyword(s):

Breast Cancer ◽

Heart Rate ◽

Heart Rate Variability ◽

Pilot Study ◽

Perception Threshold ◽

Vibration Perception Threshold ◽

Vibration Perception

Download Full-text

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Breast Cancer Research ◽

10.1186/s13058-021-01408-9 ◽

2021 ◽

Vol 23 (1) ◽

Author(s):

Erica M. Stringer-Reasor ◽

Jori E. May ◽

Eva Olariu ◽

Valerie Caterinicchia ◽

Yufeng Li ◽

...

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Dna Repair ◽

Pilot Study ◽

Expression Analysis ◽

Triple Negative Breast Cancer ◽

Gene Expression Analysis ◽

Triple Negative ◽

Egfr Inhibition ◽

Link Type

Abstract Background Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple-negative breast cancer (TNBC) with intact DNA repair, we have previously shown an induced synthetic lethality with combined EGFR inhibition and PARPi. Here, we report the safety and clinical activity of lapatinib and veliparib in patients with metastatic TNBC. Methods A first-in-human, pilot study of lapatinib and veliparib was conducted in metastatic TNBC (NCT02158507). The primary endpoint was safety and tolerability. Secondary endpoints were objective response rates and pharmacokinetic evaluation. Gene expression analysis of pre-treatment tumor biopsies was performed. Key eligibility included TNBC patients with measurable disease and prior anthracycline-based and taxane chemotherapy. Patients with gBRCA1/2 mutations were excluded. Results Twenty patients were enrolled, of which 17 were evaluable for response. The median number of prior therapies in the metastatic setting was 1 (range 0–2). Fifty percent of patients were Caucasian, 45% African–American, and 5% Hispanic. Of evaluable patients, 4 demonstrated a partial response and 2 had stable disease. There were no dose-limiting toxicities. Most AEs were limited to grade 1 or 2 and no drug–drug interactions noted. Exploratory gene expression analysis suggested baseline DNA repair pathway score was lower and baseline immunogenicity was higher in the responders compared to non-responders. Conclusions Lapatinib plus veliparib therapy has a manageable safety profile and promising antitumor activity in advanced TNBC. Further investigation of dual therapy with EGFR inhibition and PARP inhibition is needed. Trial registration ClinicalTrials.gov, NCT02158507. Registered on 12 September 2014

Download Full-text